A bipartisan US Senate panel scrutinized the Food and Drug Administration for delays and changing standards hindering rare disease treatments. Chairman Rick Scott emphasized the importance of time for families and patients with rare diseases, questioning the FDA’s efficiency in delivering safe treatments promptly. He criticized the agency for inconsistent practices and bureaucratic delays that prioritize processes over patients.
Ranking Member Kirsten Gillibrand highlighted the regulatory flexibility provided by Congress to expedite rare disease therapies but expressed concerns about its effectiveness. Witnesses, including Annie Kennedy from the EveryLife Foundation for Rare Diseases, raised issues such as the decline in drug approvals and limited opportunities for expert input in FDA decisions. Kennedy urged Congress to engage with the FDA to clarify its approach to accelerated approval.
Harvard neurologist Jeremy Schmahmann appealed to senators to address the FDA’s shortcomings, citing the rejection of a safe drug for spinocerebellar ataxia. He emphasized the importance of stability for patients on treatments and criticized the FDA’s lack of response to concerns raised. Other stakeholders, like Bradley Campbell of Amicus Therapeutics, emphasized the need for innovation and agility in rare disease treatments to prevent regulatory uncertainty from affecting US competitiveness.
Cara O’Neill from the Cure Sanfilippo Foundation highlighted current barriers faced by families seeking rare disease treatments. She pointed out instances where approvals were denied due to manufacturing concerns rather than safety issues, suggesting that the FDA could improve its review processes. The Senate committee reiterated the importance of maintaining safety standards while ensuring that the system operates with the necessary urgency for patients in need.
Rare diseases in the US affect over 30 million Americans but lack approved treatments for most conditions. Legislative measures like the Orphan Drug Act and the 21st Century Cures Act aim to incentivize treatment development and expedite approvals for serious rare diseases, reflecting ongoing efforts to address these healthcare challenges.
